Survodutide: The Other Glucagon Dual Agonist

Survodutide is a dual agonist at the GLP-1 and glucagon receptors. That pairing is what distinguishes it: tirzepatide pairs GLP-1 with GIP, and survodutide pairs it with glucagon instead.

It is investigational, with phase 3 programmes ongoing, and has no approval anywhere.

Where it sits among the incretin drugs

Read down that table and the design logic is visible. GIP and glucagon are two different additions to the same GLP-1 base, and retatrutide is the attempt to have both.

What the glucagon receptor contributes

GLP-1 works mainly on the intake side — appetite, gastric emptying, insulin response. Glucagon receptor agonism works on expenditure, increasing energy use.

Pairing an appetite mechanism with an expenditure mechanism is the rationale for both survodutide and retatrutide. It also introduces the same considerations: glucagon raises hepatic glucose output, which runs counter to what a diabetes drug conventionally aims for, and heart rate effects are tracked in trial reporting. The retatrutide side effects guide covers that tension in more detail.

Liver disease as an indication

Survodutide has been studied not only for obesity but for metabolic dysfunction-associated steatotic liver disease — the condition previously called NASH.

That focus is a reasonable consequence of the mechanism, since glucagon receptor activity acts directly on the liver. It also means some of the trial evidence addresses a different endpoint from weight, which is worth noting when comparing headline figures across compounds.

The vial math

Research vials arrive lyophilised, and the arithmetic is the same as any other injectable peptide.

The peptide calculator converts any vial and target into units.

Storage

Storage is the same as any reconstituted vial: 2–8 °C, protected from light, never frozen, and bounded by the shorter of peptide stability and the 28-day limit on bacteriostatic water. The bacteriostatic water guide covers the detail.

Frequently asked questions

Is survodutide approved?

No. It is in phase 3 trials with no approval in any major jurisdiction.

How does it differ from retatrutide?

Retatrutide adds GIP as a third target. Survodutide is GLP-1 plus glucagon only. No head-to-head trial has compared them.

Why is it studied for liver disease?

Glucagon receptors are highly expressed in the liver, so a glucagon-containing agonist has a direct rationale there that a pure incretin drug does not.